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Background: Parathyroid carcinoma (PC) mimics benign primary hyperparathyroidism
(PHP), but the diagnosis of PC is seldom available at the time of the ﬁrst operation. Because
PC is plagued by recurrences usually beyond cure, one may wonder whether some of these
could be prevented by more extensive resections initially, i.e., if the diagnosis of PC were
available at that time.
Methods: Over a 25-year period, 311 consecutive patients with PHP underwent operation in
our department: 302 had benign disease (adenomas or hyperplasias), and 9 had PC. Several
clinical parameters, serum calcium and parathyroid hormone (PTH) levels, and the weight of
the parathyroid tumor removed were compared in both groups. Receiver operating charac-
teristic curves and logistical regression analyses were used to distinguish PC from benign PHP.
Results: Eight of 9 patients with PC had symptoms, versus 238 (79%) of 302 with benign
PHP (not signiﬁcant). In the PC subgroup, serum calcium and PTH levels and the tumor
weights of the parathyroid glands removed were signiﬁcantly higher than in the benign PHP
cohort, even if these three parameters were regularly ﬂawed by low positive predictive values
(14%, 20%, and 15%, respectively).
Conclusions: Serum calcium, PTH levels, and tumor weights were signiﬁcantly greater in the
PC subgroup, even if not invariably in a discriminatory way. However, when PTH is <4 times
the upper limit of normal and tumor weight is <1.9 g, the probability of PC is nil.
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Primary hyperparathyroidism (PHP) is caused in
the vast majority of cases by parathyroid adenomas
or hyperplasias, but occasionally it is caused by
parathyroid carcinomas (PC). In all three instances,
the clinical and biological picture may be strikingly
similar.1 Because of the lack of speciﬁc clinical fea-
tures and because percutaneous aspiration biopsies
are rightly contraindicated,2 a diagnosis of PC is
difﬁcult to establish3 and is seldom available at the
time of the ﬁrst operation.1,4–9 The similarity in clin-
ical presentation is unfortunate, because PC may be
plagued by recurrences—one of the hallmarks of this
tenacious tumor10,11—and because recurrences sel-
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dom lend themselves to curative therapies, be they
surgical or conservative.2,6,11–14
Recurrences are frequently cervical (up to two
thirds of cases4 and usually within 3 years11), and one
wonders whether some of these cases could have been
prevented had the diagnosis of PC been ascertained
and, accordingly, more generous excisions had been
performed at the time of the ﬁrst operation (for in-
stance, on the contiguous thyroid lobe12 or on en-
larged nodes15).
The purpose of this study was to reevaluate the
clinical and biochemical parameters that have been
used to diﬀerentiate PC from benign PHP at the time
of the ﬁrst operation. To achieve this, patients with
benign PHP were compared retrospectively with pa-
tients with PC who underwent operation in the same
department during the same period of time. Param-
eters studied included the age and sex of the patients,
the presence and type of symptoms, preoperative
levels of serum calcium and parathyroid hormone
(PTH), and the tumor weight of the parathyroid
glands removed. Comparing two groups of such un-
even sizes entails certain statistical precautions, which
are discussed below.
MATERIALS AND METHODS
Over a 25-year period (June 1976 to December
2001), 311 consecutive patients (82 men and 229
women, aged 16–92 years; mean ± SD, 60.5 ± 15.2
years) underwent operation in the Department of
Surgery of Geneva University Hospital for PHP: 242
had adenomas (78%), 60 had hyperplasias (19%), and
9 had PC (3%). In the PC subgroup, there were seven
women and two men, aged 35 to 67 years
(mean ± SD, 54.9 ± 9.9 years); none of them had a
family history of PC. PC was deﬁned by Schantz and
Castelmans criteria,16 which include any of the fol-
lowing: (1) local invasion of contiguous structures; (2)
nodal or distant metastases; and (3) capsular or vas-
cular invasion, thick ﬁbrous bands, pleiomorphic
cells in a trabecular pattern, or mitoses (Fig. 1).
FIG. 1. Histological appearance of parathyroid adenoma (A) and carcinoma (B--D). (A) Adenoma is lined by a capsule, and nontumorous
glandular parenchyma is compressed (upper right corner; stain, hematoxylin and eosin; original magniﬁcation, ·100). (B) Parathyroid
carcinoma: tumor (T) invades the capsule (black arrows). M, muscle (stain, hematoxylin and eosin; original magniﬁcation, ·20). (C) Carci-
nomatous cells are separated by thick ﬁbrous bands (stain, hematoxylin and eosin; original magniﬁcation, ·100). (D) Tumor invasion (T) is
seen within a blood vessel (arrowheads; stain, hematoxylin and eosin; original magniﬁcation, ·200).
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Symptoms were looked for in the entire PHP group
and allocated to six possible categories: general (fati-
gue, weight loss, and anorexia), articular and/or skel-
etal (osteopenia or osteoporosis as measured by dual-
energy x-ray absorptiometry, according to the World
Health Organization criteria17), renal (nephrolithiasis,
nephrocalcinosis, or impaired renal function in the
absence of any other etiology), gastrointestinal (an-
orexia, nausea, vomiting, dyspepsia, vague abdominal
complaints, and constipation18), hypertensive, and
TABLE 1. Characteristics of patients with parathyroid carcinoma (n = 9)
Patient no. Sex/age (y) Symptoms s-Ca s-P s-PTH OP
Time of
diagnosis Follow-up (y)
1 M/35 U, T, pancreatitis 3.93 ﬂ 19.4 IR + R thyroid
lobectomy
After OP NED 25.2
2 F/62 O, U, T 5.99 1.70 6.9 IL After OP NED 21.3
3 F/51 O, U 2.4–2.8 1.9–3.5 12.8 SR During OP DOC 3.0
(myocardial
infarct)
4 F/57 O, U, T 2.71 ﬂ 4.6 IR After OP NED 16.6
5 F/45 None 3.60 .40 4.1 IL During OP DOC 5.0
(alcohol
abuse)
6 M/56 O, U 3.28 .79 6.4 SR + R thyroid
lobectomy + LN
During OP NED 8.6
7 F/63 O, palpable
cervical mass
3.27 .66 20.0 Lx2 + L thyroid
lobectomy
During OP NED 3.8
8 F/67 T 2.91 .52 4.0 IL+ L thyroid
lobectomy
After OP NED 2.0
9 F/58 O, U 3.02 .59 13.8 IL + total
thyroidectomy
During OP NED 1.3
OP, operation; U, urinary symptoms; T, thymic disorders; IR, inferior right; R, right; NED, no evidence of disease; O, osteoarticular
symptoms; IL, inferior left; SR, superior right; DOC, dead of other cause; LN, lymph node; L, left; s-Ca, calcium in serum;
s-P, phosphorus in serum; s-PTH, parathyroid hormone in serum; Lx2, bilateral thyroid lobectomy (total thyroidectomy).
Reference values: p-Ca, 2.20 to 2.52 mmol/L; p-P, .80 to 1.40 mmol/L.
TABLE 2. Cases of parathyroid cancer (PC) compared with all cases of benign primary hyperparathyroidism (PHP) operated
on during the same period
Variable PC Benign PHP P value
No. of cases 9 302 –
Age (y) NS
Mean ± SD (range) 54.9 ± 9.9 (35–67) 60.7 ± 15.4 (16–92)
Median (IQR) 57 (11) 62 (21)
Sex, M/F (% men) 2/7 80/222 (26%) NS
Patients with symptoms 8 238 (79%) NS
General symptoms 4 68 (23%) NS
Skeletal involvement 5 84 (28%) <.003
Renal involvement 5 84 (28%) NS
Renal and skeletal involvement 5 13 (4%) <.0001
Thymic disorders 3 47 (16%) NS
GI symptoms 1 39 (13%) NS
Hypertension 0 52 (13%) NS
s-Ca (mmol/L) .04
Mean ± SD (range) 3.4 ± 1.1 (2.6–6.0) 2.9 ± .3 (2.0–4.8)
Median (IQR) 3.3 (.8) 2.8 (.4)
s-PTH (· upper range of normal value) <10)5
Mean ± SD (range) 10.3 ± 6.5 (4.0–20.0) 2.6 ± 2.2 (.5–24.1)
Median (IQR) 6.9 (9.3) 2.0 (1.5)
Tumor weight (g) <10)5
Mean ± SD (range) 4.9 ± 2.1 (1.9–8.0) 1.3 ± 2.2 (.015–14.9)
Median (IQR) 5.3 (3.2) .6 (1.0)
NS, not signiﬁcant; IQR, interquartile range; GI, gastrointestinal; s-Ca, calcium in serum; s-PTH, parathyroid hormone in serum.
Continuous variables were compared by using the Mann-Whitney test, and proportions were compared by using Fishers exact test.
Symptoms are detailed in the text (see Materials and Methods). Reference values for p-Ca are 2.20 to 2.52 mmol/L.
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thymic (or mood disorders). Starting in February
1986, all patients who underwent operation (5 with PC
and 251 with benign PHP) received methylene blue in
the hour preceding surgery to facilitate identiﬁcation
of the parathyroid gland involved.19
Summary results are given as mean ± SD. Com-
parisons between two groups for continuous vari-
ables were performed with a Mann-Whitney test.
Fishers exact test was used for comparing propor-
tions.
Receiver operating characteristic curves were used
to determine the performance of two serum param-
eters (calcium and PTH) and the weight of the
parathyroid tumor removed to evaluate their ability
to predict PC before surgery. Logistical regression
was used to estimate the probability of diagnosing a
PC based on serum calcium and PTH levels and the
weight of the tumor. The eﬀect of predictive variables
was assessed by odds ratio (OR) and 95% conﬁdence
intervals. The signiﬁcance levels for two-sided
P values was .05 in all tests. The data were analyzed
with Stata software, release 7.0 (StataCorp LP, Col-
lege Station, TX).
RESULTS
Characteristic features of patients with PC are lis-
ted in Table 1 and are compared in Table 2 with those
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FIG. 2. Box plots for tumor weight and serum calcium and para-
thyroid hormone (PTH) determinations in the benign primary
hyperparathyroidism (PHP) and carcinomatous cohorts. Tumor
weights are provided in grams, serum calcium levels in millimoles
per liter, and PTH values as multiples of the upper range of normal
values.
TABLE 3. Weight of parathyroid glands and microscopic features of malignancy according to Schantz and Castleman16 found in
nine patients with PC
Patient no. Sex/age (y)
Weight of gland
removed (g)
Capsular or vascular
invasion
Thick ﬁbrous
bands
Pleiomorphic cells, trabecular
pattern, or mitoses
1 M/35 6.0 Vascular invasion ) Trabecular pattern
2 F/62 2.2 Capsular + vascular invasion ) –
3 F/51 5.0 Vascular invasion + –
4 F/57 6.5 Capsular invasion + –
5 F/45 8.0 Capsular + vascular invasion ) –
6 M/56 4.0 Capsular + vascular invasion + –
7 F/63 NA – + Mitoses
8 F/67 1.9 Vascular invasion + Mitoses
9 F/58 5.7 Capsular invasion ) Trabecular pattern
PC, parathyroid carcinoma; NA, not available.
0
5
10
15
20
25
tu
m
or
 w
ei
gh
t
2
3
4
5
6
se
ru
m
 c
al
ci
um
0
5
10
15
20
PT
H
benign PHP carcinoma
FIG. 3. Receiver operating characteristic (ROC) curves achieved
by tumor weights, serum calcium, and parathyroid hormone (PTH)
determinations. Areas under ROC curves measure .7051 for serum
calcium determinations, .9446 for tumor weights, and .9601 for
PTH determinations. PHP, primary hyperparathyroidism.
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of all patients who underwent operation for benign
PHP during the same period. Eight of the nine pa-
tients with PC had symptoms, versus 238 of 302 in the
benign PHP group (not signiﬁcant). Compared with
patients who had adenomas and hyperplasias, pa-
tients with PC were more likely to have bone disease
(P < .003) or concomitant bone and renal disease (P
< .0001). However, for a given level of increased
PTH, symptoms as a whole were evenly distributed
whether patients had PC or benign PHP. Within the
PC subgroup, one patient presented with a palpable
neck mass, but none had preoperative (or post-
operative) vocal cord paralysis, and none had re-
gional (lymph nodes) or distant metastases at the
time of diagnosis.
The nine patients with PC had their pathologic
gland removed, and frozen sections were performed.
The gland removed was described as ﬁrm in one case,
dark in another, and adherent or ‘‘in continuity’’ with
the thyroid (in three) or the esophagus (in one).
Microscopic criteria for malignancy according to
Schantz and Castleman16 are listed in Table 3. Car-
cinomatous glands were signiﬁcantly bigger than
adenomatous and hyperplastic glands (4.9 ± 2.1 g
vs. 1.3 ± 2.2 g, respectively; P < .00001).
Frozen sections were unable to prove cancer in
four patients. Excision of the thyroid lobe adjacent
to PC was performed in ﬁve patients (three times
in a second step upon receipt of the deﬁnite
diagnosis) because deﬁnite slides had shown the
surgical section to be invaded. In none of these
three cases, however, did histology conﬁrm inva-
sion of the thyroid tissue removed. In two in-
stances, thyroidectomy was added because of
intrinsic benign thyroid pathologies, irrespective of
PC. In addition to thyroid lobectomy, one patient
had benign-looking internal jugular lymph nodes
removed, and these also proved benign. No adju-
vant treatment was proposed for any of the PC
patients.
Two patients with PC died of unrelated causes
3 and 5 years after surgery. The remaining seven
patients with PC are alive after a median follow-up
period of 8 years (range, 3 months to 20 years), and
yearly serum calcium determinations are so far
within the normal range.
The ability of increased PTH levels and tumor
weights to predict PC was considerably greater than
that of hypercalcemia (Figs. 2 and 3 and Table 4),
even though serum calcium levels were also higher in
the PC subgroup (Table 2). For the four patients
whose cancers were undiagnosed during surgery,
both PTH levels and tumor weights exceeded
respective cutoff values.
To evaluate the probability of diagnosing PC, a
logistic regression method was used that was based
on serum calcium and PTH levels and the weight of
the tumor removed (Table 5). Crude OR showed
that patients with higher levels of serum calcium and
PTH and heavier tumor weights were more likely to
have PC. After adjusting for tumor weight and
serum calcium, the OR associated with PTH did not
change, whereas the discriminating effect of tumor
weight and calcium both disappeared (this means
that all discriminative information can be derived
from PTH levels alone). The R2 value was .26, and
this means that approximately one fourth of the
variance was explained by these three factors.
TABLE 4. Ability of serum calcium, PTH levels, and tumor weight to differentiate PC from benign PHP
Variable Cutoff value Sensitivity Speciﬁcity PPV NPV
Ca (mmol/L) 3.27 56 (21–86) 90 (76–93) 14 99
PTH (pmol/L or nmol/L) 4 · N 100 (66–100) 88 (83–91) 20 100
Tumor weight (g) 1.9 100 (66–100) 81 (76–86) 15 100
Except for cutoﬀ values, all ﬁgures are percentages; numbers in parentheses are 95% conﬁdence levels.
PTH, parathyroid hormone; PC, parathyroid carcinoma; PHP, primary hyperparathyroidism; PPV, positive predictive value; NPV,
negative predictive value; N, upper range of normal value.
TABLE 5. Odds ratio (OR) estimate of parathyroid cancer compared with benign primary hyperparathyroidism
Variable Crude OR 95% CI P value Adjusteda OR 95% CI P value
Tumor weight 1.28 1.07–1.52 .006 .97 .78–1.19 .743
Serum calcium 5.51 1.86–16.35 .002 2.29 .73–7.18 .156
PTH 1.39 1.22–1.59 .000 1.37 1.16–1.61 .000
CI, conﬁdence interval; PTH, parathyroid hormone.
aAdjusted variables were tumor weight, serum calcium, and PTH; all variables were mutually adjusted.
PARATHYROID CARCINOMA 5
Ann. Surg. Oncol. Vol. 12, No. 7, 2005
DISCUSSION
Several factors account for the diﬃculty in estab-
lishing a correct diagnosis of PC. First, PC mimics
benign PHP clinically, and given the rarity of PC (it
never exceeds 5% of cases of benign PHP in series of
respectable sizes: 2.9% in ours but 1% in most ser-
ies9,11,12,20), the diagnosis is seldom suspected. Sec-
ond, although parathyroid inﬁltration into adjacent
neck structures is obviously synonymous with
PC,3,4,15,21 such extreme conditions are not the rule:
only 38 cases (28%) in a 1991 Japanese survey of 138
cases20 (however, some degree of adherence to the
thyroid gland is quite regularly observed22—four
times in the present series).
Thus, the scarcity in PC of macroscopic signs
customarily suggestive of neoplasia (as in this series)
may account for changes in the histological criteria of
the disease, because most authors18 have now adop-
ted Schantz and Castlemans16 deﬁnition, by which
more discrete histological features sufﬁce in estab-
lishing a diagnosis of PC.1,3 These features (which
have been used in this study) include possible com-
binations of the following: a trabecular pattern, mi-
totic ﬁgures, thick ﬁbrous bands, or capsular and
blood vessel invasion. For obvious reasons, diagnosis
is even more difﬁcult in the frozen-section setting8
(incorrect in four of our nine cases) and may lead to
parsimonious tumor resections in conditions when
more generous ones (if not necessarily more curative)
would seem safer.
Curiously enough, PC frequently displays other
features that may facilitate its diagnosis before sur-
gery. Female prevalence is not as striking as in
PHP,10,14,16,20,23,24 and patients tend to be younger,
even though neither sex nor age reached statistical
signiﬁcance in this report.9 All but one of our nine
patients were clearly symptomatic; the most dis-
criminative ﬁnding in our series was a combination of
urinary and skeletal symptoms10,14,22 (it is indeed a
classic feature of PC to be more frequently and more
severely symptomatic compared with benign
PHP1,18). A palpable neck mass,6,8,10 described in
nearly 1 in 3 cases of PC in a series of 61,16 was noted
only once in this study.
The severity of hypercalcemia may prove more
useful than symptoms for suggesting PC before sur-
gery: whereas the 302 patients with benign PHP had
calcemias averaging 2.89 ± .33 mmol/L, for the 9
patients with PC, levels increased to 3.45 ± 1.05
mmol/L (a signiﬁcant diﬀerence; P < .04). Such
differences have already been reported9; several series
have shown 65%20 to 75%4 of PC patients with
calcemias >3.5 mmol/L. Despite such differences,
the sensitivity and, particularly, the positive predic-
tive value of serum calcium for PC are disappointing
(56% and 14%, respectively), as reﬂected by a con-
siderable overlapping of patients with PC and benign
PHP (Fig. 2). Increments are more striking for mean
PTH determinations18,20: 2.6 times the upper level of
normal value in cases of benign PHP, versus 10.3 in
PC (P < 10)5). This was conﬁrmed in a series of 43
cases from the Mayo Clinic (mean increase, 10.2
times the upper limit of normal)14 but was not the
case in a smaller California report, which failed to
disclose signiﬁcant differences in PTH levels between
adenomas and PC.22 To a slightly lesser degree, the
same holds true for tumor weight, a ﬁnding clearly
demonstrated in an American series in which 10 PC
patients had parathyroid glands exceeding 2.5 g
(mean, 7.2 g).6 Although more promising than serum
calcium, PTH increments and tumor weight are un-
able to predict PC reliably in all instances (indeed,
when the prevalence of a disease is low, false-positive
results can be expected to outnumber true-positive
ones: even when the sensitivity and speciﬁcity of a
given test are high, the positive predictive value is still
low). However, the probability of PC was nil in our
series when the PTH was increased <4 times the
upper limit of normal, the tumor weight was <1.9 g,
or both.
The most eﬀective treatment in PC is surgical and
should consist of an en-bloc resection, avoiding
rupture and spillage of the tumor.20 In the event of a
correct diagnosis of PC being available during sur-
gery (and, obviously, also before), attention should
be given to the possible invasion of the resection
margins. Doubt on the thyroid side (or the presence
of nodular thyroid disease) should entail en-bloc
ipsilateral thyroidectomy13 (even though histology
may fail to ﬁnd residual cancer in the thyroid speci-
men resected, as occurred four times in this series).
By the same token, jugular lymph node dissection
should be performed only in cases of grossly enlarged
lymph nodes, a situation reported 9 times in 18 pa-
tients with metastatic disease in a series of 5916: we
performed it once in a patient with normal-appearing
nodes, but histology failed to disclose lymphatic
metastases. This rather aggressive attitude seems
justiﬁed by the futility of repeat surgery22,25 or of
other more conservative treatments in case of recur-
rent PC.2,6,11–14
In conclusion, there are intraoperative indications
clearly suggestive of PC, such as gland ﬁrmness or
inﬁltration into adjacent structures, usually the thy-
roid. These ﬁndings, however, may be absent, as in
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this series. Consequently, one should seriously con-
template the diagnosis of PC in the presence of an
abnormally large parathyroid gland and/or of
unusually high levels of serum calcium or—better
still—of PTH, even if this study failed to pinpoint
irrefutable and pathognomonic cutoﬀ values for these
three parameters to assess PC. However, the diagnosis
of PC can be reliably ruled out for the many patients
in whom PTH increments are inferior to 4 times the
upper limit of normal range, tumor weights are <1.9
g, or both, and this should help to reassure the sur-
geon who renounces extensive resections, because the
probability of PC is nil below these values.
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